By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


GlycoMimetics, Inc. 

14915 Broschart Road, Suite 200

Rockville   Maryland  20850  U.S.A.
Phone: 301-738-1166 Fax:




Company News
GlycoMimetics, Inc. (GLYC) Doses First Patient In Phase 1 Clinical Trial Of Drug Candidate GMI-1271 For Multiple Myeloma 9/14/2016 11:06:10 AM
GlycoMimetics, Inc. (GLYC) Initiates Dosing In Phase I Clinical Trial Of GMI-1359 9/6/2016 11:01:12 AM
GlycoMimetics, Inc. (GLYC) Announces Publication Of Preclinical Data Showing Drug Candidate GMI-1271 Reduces Inflammatory Responses After Heart Attack 8/16/2016 9:18:03 AM
GlycoMimetics, Inc. (GLYC) To Present At Canaccord Genuity 36th Annual Growth Conference 8/8/2016 11:45:50 AM
GlycoMimetics, Inc. (GLYC) Reports Second Quarter 2016 Results 8/5/2016 11:09:15 AM
GlycoMimetics, Inc. (GLYC) Doses First Patient In Phase 2 Portion Of Clinical Trial Of GMI-1271 In Newly Diagnosed Acute Myeloid Leukemia 6/28/2016 10:22:05 AM
GlycoMimetics, Inc. (GLYC) Announces Proposed Public Offering Of Common Stock 6/17/2016 10:02:20 AM
GlycoMimetics, Inc. (GLYC) Announces Pricing Of Public Offering Of Common Stock 6/17/2016 8:18:49 AM
GlycoMimetics, Inc. (GLYC)’ GMI-1271 Receives FDA Fast Track Designation For Treatment Of Acute Myeloid Leukemia 6/13/2016 8:19:15 AM
GlycoMimetics, Inc. (GLYC)’ GMI-1271 Yields High Remission Rates And Favorable Tolerability In Phase I Portion Of Phase I/II Clinical Trial For AML 6/10/2016 8:28:06 AM